Starbucks denies that its decision to stop selling Chicken, Maple Butter, and Egg Sandwich on June 26, a mere five days after it had been announced as a new permanent menu item, was due to FDA recall or salmonella or listeria contamination.
A Starbucks spokesperson said that the Chicken, Maple Butter, and Egg Sandwich was given a voluntary stop sell and discard order by the company because it didn't live up to the company's high standards for quality.
The quality issue that was identified by Starbucks was simply about taste or based on another issue and would not lead to food-borne illness and any reports linking the stop sale to illness are inaccurate.
The spokesperson added that Starbucks is devoted to providing high-quality products, and anytime a concern about a product or its quality is expressed, we always proceed with extreme caution.


Yes, government influences wages – but not just in the way you might think
Asian Markets Slide as Silver Volatility, Earnings Season, and Central Bank Meetings Rattle Investors
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
EU Recovery Fund Faces Bottlenecks Despite Driving Digital and Green Projects
RBA Raises Interest Rates by 25 Basis Points as Inflation Pressures Persist
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Glastonbury is as popular than ever, but complaints about the lineup reveal its generational challenge
Stuck in a creativity slump at work? Here are some surprising ways to get your spark back
The ghost of Robodebt – Federal Court rules billions of dollars in welfare debts must be recalculated
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 



